

Mirko Farina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3822873/publications.pdf>

Version: 2024-02-01

40
papers

503
citations

840776
11
h-index

677142
22
g-index

42
all docs

42
docs citations

42
times ranked

762
citing authors

#	ARTICLE	IF	CITATIONS
1	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	2.8	63
2	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. <i>Blood</i> , 2018, 132, 547-550.	1.4	61
3	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	1.4	57
4	The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 1674-1682.	4.1	45
5	Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. <i>Hematological Oncology</i> , 2017, 35, 828-834.	1.7	36
6	Prognostic role of baseline ¹⁸ F-FDG PET/CT parameters in MALT lymphoma. <i>Hematological Oncology</i> , 2019, 37, 39-46.	1.7	33
7	Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2133-2144.	4.0	27
8	Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2224-2233.	2.4	23
9	Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?. <i>American Journal of Hematology</i> , 2016, 91, 507-517.	4.1	21
10	RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?. <i>Case Reports in Oncology</i> , 2021, 13, 1263-1269.	0.7	18
11	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534268.	3.7	16
12	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021, 56, 2272-2275.	2.4	12
13	Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These "Magic Bullets". <i>Biology</i> , 2021, 10, 105.	2.8	11
14	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 754-762.	1.7	9
15	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	2.8	9
16	Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. <i>Cells</i> , 2021, 10, 2764.	4.1	8
17	Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
18	ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Family Clinical Trial. <i>Case Reports in Hematology</i> , 2020, 2020, 1-7.	0.4	7

#	ARTICLE	IF	CITATIONS
19	The possible role of mutated endothelial cells in myeloproliferative neoplasms. <i>Haematologica</i> , 2021, 106, 2813-2823.	3.5	7
20	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. <i>Acta Haematologica</i> , 2016, 135, 39-42.	1.4	6
21	Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?. <i>Frontiers in Oncology</i> , 2020, 10, 564521.	2.8	5
22	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. <i>Cells</i> , 2022, 11, 553.	4.1	5
23	Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms. <i>Cells</i> , 2021, 10, 445.	4.1	4
24	Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF). <i>Blood</i> , 2019, 134, 1684-1684.	1.4	3
25	Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 6-7.	1.4	3
26	Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach. <i>Blood</i> , 2018, 132, 4387-4387.	1.4	1
27	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	1.4	1
28	Extended Mutational Profiling By MSK-IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. <i>Blood</i> , 2019, 134, 633-633.	1.4	1
29	CT-027: Multidimensional Geriatric Assessment for Elderly Hematological Patients (≥60 years) Submitted to Allogeneic Stem Cell Transplantation; A French-Italian 10-year Experience on 228 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S213-S214.	0.4	0
30	CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients ≥50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S452.	0.4	0
31	Poster: CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients ≥50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S258.	0.4	0
32	Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance?. <i>Blood</i> , 2013, 122, 1549-1549.	1.4	0
33	Can Allo-HSCT Improve the Poor Clinical Outcome of the 'Internal Tandem Duplication' of the FLT3 Gene?. <i>Blood</i> , 2014, 124, 5938-5938.	1.4	0
34	Alternative Splicing of hTERT Exon 7 in AML: Biological Function and Prognostic Significance. <i>Blood</i> , 2014, 124, 1019-1019.	1.4	0
35	A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs). <i>Blood</i> , 2015, 126, 4952-4952.	1.4	0
36	The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available. <i>Blood</i> , 2016, 128, 2882-2882.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years. Blood, 2016, 128, 3993-3993.	1.4	0
38	Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up. Blood, 2018, 132, 5435-5435.	1.4	0
39	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. Blood, 2018, 132, 4251-4251.	1.4	0
40	R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients. Blood, 2019, 134, 4146-4146.	1.4	0